ArticleHeart Asia2016
Choice of prosthetic heart valve in a developing country.
Article in Heart Asia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 36 citations in OpenAlex.
- Life-expectancy paradox and the selection of older patients with aortic stenosis for valve intervention.Open heart · 2026Review
- Outcomes of mechanical and bioprosthetic surgical valve replacements in egypt: evidence from a narrative review and experts' survey.Journal of cardiothoracic surgery · 2026Review
- Safety and efficacy of transcatheter aortic valve replacement in rheumatic aortic regurgitation: a prospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- Polymeric mitral valve replacement in rheumatic heart disease: hemodynamic and early clinical outcomes from a dedicated sub-analysis of the India Surgical Trial.Frontiers in cardiovascular medicine · 2026Article
- Article
- Polymeric Heart Valves: Do They Represent a Reliable Alternative to Current Prosthetic Devices?Polymers · 2025Review
- Nurses' knowledge, attitudes, and practices about rehabilitation of patients after heart valve surgery in Namibia.Health SA = SA Gesondheid · 2024Article
- Hemodynamic Effects of Subaortic Stenosis on Blood Flow Characteristics of a Mechanical Heart Valve Based on OpenFOAM Simulation.Bioengineering (Basel, Switzerland) · 2023Article
- Mechanical prosthetic valve thrombosis in current era: 5-year follow-up.Indian journal of thoracic and cardiovascular surgery · 2021Article
- Expanding Valve Repair in Rheumatic Heart Disease.Frontiers in cardiovascular medicine · 2021Article
- Rheumatic aortic valve disease-when and who to repair?Annals of cardiothoracic surgery · 2019Article
- Rebuttal to: choice of prosthetic valve in a developing country.Heart Asia · 2016Article
- Perioperative management of patients with prosthetic heart valves-A narrative review.Annals of cardiac anaesthesiaReview
- Continued use of Warfarin in lower dose has safe maternal and neonatal outcomes in pregnant women with Prosthetic Heart Valves.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mechanical prostheses and stented xenografts (bioprosthesis) are most commonly used substitutes for aortic and mitral valve replacement. The mechanical valves have the advantage of durability but are accompanied with the risk of thromboembolism, problems of long-term anticoagulation, and associated risk of bleeding. In contrast, bioprosthetic valves do not require long-term anticoagulation, but carry the risk of structural valve degeneration and re-operation. A mechanical valve is favoured in young patients (<40 years) if reliable anticoagulation is ensured. In elderly patients (>60 years), a bioprosthesis is a suitable substitute. In middle-aged patients (40-60 years), risk of re-operation in a bioprosthesis is equal to that of bleeding in a mechanical valve. Traditionally, a bioprosthesis is opted in patients with limited life expectancy. Calculation of life expectancy, based solely upon chronological age, is erroneous. In developing countries, the calculated life expectancy is much lower than that of Western population, hence age related Western cut-offs are not valid in developing countries. Besides age, cardiac condition of the patient, systemic illnesses, socio-economic status, gender and geographical location also decide the life expectancy of the patients. Selection of the prosthetic valve substitute should be based on: aspiration of the patient, life expectancy, socio-economic and educational background, occupation of the patient, availability, cost, monitoring of anti-coagulation, monitoring of valve function and other valve related complications, and possibility of re-operation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.